It is the patients with kidney disease who will lead us to the understanding of pathways and targets that will drive transformative drug development. To accomplish this, we will partner with patients to build the world’s most comprehensive registry of individuals with molecularly defined kidney disease.
Goldfinch is assembling a database of genetic, genomic and clinical information from consented patients who have provided thousands of DNA samples and anonymized clinical records. Building off of the studies of our founders and partners, we will deeply study DNA and correlate findings with clinical data. We will then use novel computational tools to mine for evidence of the DNA variants that increase risk for kidney disease and suggest new ways to treat and prevent it.